archer fusionplex sarcoma v2 panel (Integrated DNA Technologies)
Integrated DNA Technologies is a verified supplier 
Integrated DNA Technologies manufactures this product 
99
Structured Review
Integrated DNA Technologies
archer fusionplex sarcoma v2 panel
Archer Fusionplex Sarcoma V2 Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 291 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/archer+fusionplex+sarcoma+v2+panel/Archer+FUSIONPlex+Sarcoma+v2+panel/custom%40fusionplex-sarcoma-v2-panel%4042471200
Average 99 stars, based on 291 article reviews
Archer Fusionplex Sarcoma V2 Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 291 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/archer+fusionplex+sarcoma+v2+panel/Archer+FUSIONPlex+Sarcoma+v2+panel/custom%40fusionplex-sarcoma-v2-panel%4042471200
Average 99 stars, based on 291 article reviews
archer fusionplex sarcoma v2 panel - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
Morphology:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Analysis:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Staining:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Isolation:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Sequencing:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Biomarker Discovery:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Methylation:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Next-Generation Sequencing:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the DNA Methylation Assay:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Generated:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the In Situ:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the In Situ Hybridization:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Fluorescence In Situ Hybridization:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Hybridization:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Fluorescence:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the RNA Sequencing:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Multiplex Assay:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the Immunohistochemical staining:Article Title: Immunoreactivity of GPNMB (glycoprotein nonmetastatic melanoma protein B) across the spectrum of uterine mesenchymal tumours. Article Snippet: and Melan-A, with only one tumour showing HMB45 positivity in isolated cells, whereas the remaining cases were negative for both melanocytic markers. Three GPNMB-positive LMSs were analysed using the |